IONIS DGAT2Rx

Drug Profile

IONIS DGAT2Rx

Alternative Names: IONIS-DGAT2Rx; ISIS 484137; ISIS-DGAT2Rx

Latest Information Update: 14 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Ionis Pharmaceuticals
  • Class Antisense oligonucleotides
  • Mechanism of Action Diacylglycerol O acyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-alcoholic steatohepatitis; Type 2 diabetes mellitus

Most Recent Events

  • 08 Nov 2017 Phase-II clinical trials in Non-alcoholic steatohepatitis in Canada (Parenteral) (NCT03334214)
  • 08 Nov 2017 Phase-II clinical trials in Type-2 diabetes mellitus in Canada (Parenteral) (NCT03334214)
  • 18 Dec 2015 Isis Pharmaceuticals is now called Ionis Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top